6th International Conference on
Drug Delivery and Formulations

Biography:

Panpan Ma has been a PhD student in the Faculty of Health (Université Paris Cité) since 2019 under the supervision of Dr. Yohann Corvis. She focuses on the preparation of anti-cancer and anti-inflammatory nanocrystal suspensions by using a solvent/antisolvent precipitation approach. The original nanocrystals prepared present targeting and sustained release properties, modifying the therapeutic impact of the drug. Her work includes synthesis of nanocrystals, structural characterization, dissolution studies, in vitro and in vivo studies, emphasizing the advantages of innovative drug delivery systems.

Abstract:

Up to 90% of the active pharmaceutical ingredients (API) currently in development present low solubility because approximately 65% and 15% belong to Class II and Class IV of the biopharmaceutical classification system (BCS), respectively. 1 Therefore, in order to develop new drugs towards clinical applications, improving API solubility is a major challenge for the pharmaceutical field. Crystal nanosuspensions, otherwise known as nanocrystals (NCs), consisting of pure API stabilized by a surface-active agent, have emerged as one of the most promising approaches for overcoming bioavailability issues. This allows optimizing the therapeutic efficiency of the NC drugs with better safety and targeting properties, while being administrated through various routes.2,3 The UTCBS lab pioneered the bottom-up approach with minimal amount of Pluronic®F-127 as stabilizer to engineer etoposide (BCS class IV) NCs for anti-cancer treatment, which strengthened the feasibility of drug NCs as effective delivery systems for nanomedicines administered parenterally and with lower side effects than the related marketed product, Toposar®. 4 Interestingly, around 40 NC drug formulations are in market and under clinical trials, but only two marketed antiinflammatory products have been approved by the U.S. Food and Drug Administration (i.e. Naprelan® and Acticoat®, approved in 2006 and 2008, respectively), and another one, the anti-inflammatory drug Paxceed®, is currently on phase III of clinical trial. 5 The present work consists of developing our expertise on anti-cancer therapeutic NCs with other API pharmaceutical classes like anti-inflammatory with curcumin (BCS class IV), a typical natural compound extracted from turmeric， and prednisolone (non-classified BCS class), a synthetic cortisol compound. For that purpose, two different Pluronic®derivatives, namely Pluronic® F-127 and F-68 were evaluated. By optimizing several experimental parameters, the API/stabilizing agent ratio were adjusted to screen out the best formulation of nanocrystal with convenient yield, high stability, sustained release performance and improved therapeutic activity.